id,brand_name,generic_name,manufacturer,logo_url,indication,DailyMed_drug_label_link,dosing,primary_endpoints,rwd_measures,pro_measures,section_drug_identification,section_disease_context,section_drug_development_timeline,section_clinical_evidence,section_heor,section_rwe,section_pros,section_comparative_positioning,section_payer_landscape,section_research_opportunities,
drug1,AMVUTTRA®,vutrisiran,"Alnylam Pharmaceuticals, Inc",https://www.pantherxrare.com/wp-content/uploads/2024/08/Amvuttra-logo.png,"Polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults; cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality, cardiovascular hospitalizations, and urgent heart failure visits ([US PI](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8db0facb-81b6-4006-9239-27dc6409c5d3)).",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8db0facb-81b6-4006-9239-27dc6409c5d3,"25 mg subcutaneous (SC) injection administered by a healthcare professional once every 3 months (Q3M); if a dose is missed, administer as soon as possible and resume Q3M from most recent injection; vitamin A supplementation is required due to treatment-induced reduction in serum vitamin A ([PI](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8db0facb-81b6-4006-9239-27dc6409c5d3), [product characteristics PDF](https://www.alnylamassist.com/sites/default/files/pdfdownloads/amvuttra-vutrisiran-product-characteristics.pdf)).","HELIOS-A (hATTR-PN): change from baseline in modified Neuropathy Impairment Score +7 (mNIS+7) at 18 months vs external placebo; key secondary endpoints included change in Norfolk QoL-DN total score, gait speed (10-meter walk test), modified BMI, and serum transthyretin (TTR) reduction ([Adams 2023, Amyloid](https://pubmed.ncbi.nlm.nih.gov/35875890/)). HELIOS-B (ATTR-CM): primary composite of all-cause mortality and recurrent cardiovascular events (CV hospitalizations and urgent HF visits) to ≈36 months; hierarchical win-ratio analysis incorporating 6-minute walk distance (6MWD) and Kansas City Cardiomyopathy Questionnaire overall summary score (KCCQ-OS) ([Fontana 2024, NEJM](https://pubmed.ncbi.nlm.nih.gov/39213194/), [Witteles 2025, JACC](https://www.jacc.org/doi/10.1016/j.jacc.2025.04.008)).","Real-world measures commonly used in ATTR hATTR-PN/ATTR-CM populations include overall survival and cardiovascular mortality; hospitalization rates (all-cause, HF-specific, CV-specific); emergency/urgent HF visits; neurologic progression (NIS/mNIS+7, modified BMI, ambulation status); NYHA class; use of disease-modifying therapies (tafamidis, acoramidis, patisiran, inotersen, vutrisiran); treatment persistence, adherence and switching; healthcare resource utilization (inpatient days, outpatient visits, ED visits, procedures such as pacemakers/ICDs and transplant); and total/ATTR-related costs captured in registries (e.g., THAOS) and claims-based cohorts ([Gentile 2023, THAOS](https://pubmed.ncbi.nlm.nih.gov/37946256/), [Garcia-Pavia 2025, THAOS tafamidis RWE](https://pubmed.ncbi.nlm.nih.gov/38909877/), [vutrisiran HCRU abstract](https://www.ahajournals.org/doi/abs/10.1161/circ.152.suppl_3.4369360)).","Key PRO instruments include disease-specific neuropathy and ATTR tools (Norfolk Quality of Life-Diabetic Neuropathy [Norfolk QoL-DN], Neuropathy Impairment Score/mNIS+7, modified Rankin Scale, and emerging ATTR-QoL scales); cardiac-specific measures (KCCQ-OS, NYHA class, 6MWD, echocardiographic parameters); and generic HRQoL utilities (EQ-5D, SF-36/SF-12). These instruments are used in pivotal RNAi trials (APOLLO for patisiran, HELIOS-A/B for vutrisiran) and burden-of-illness studies to quantify functional decline and treatment benefit ([Yarlas 2019, Muscle Nerve](https://pubmed.ncbi.nlm.nih.gov/31093980/), [Obici 2020, QoL in APOLLO](https://www.tandfonline.com/doi/full/10.1080/13506129.2020.1730790), [Fontana 2024, NEJM HELIOS-B](https://pubmed.ncbi.nlm.nih.gov/39213194/)).","AMVUTTRA® (vutrisiran) is a transthyretin-directed small interfering RNA (siRNA) therapeutic in the class of transthyretin-directed RNA interference agents. It is conjugated to a triantennary N-acetylgalactosamine (GalNAc) ligand for targeted uptake into hepatocytes, where it engages the RNA-induced silencing complex to degrade both mutant and wild-type TTR mRNA, producing rapid and sustained ≈80–90% reductions in circulating TTR and thereby reducing amyloid formation at its source ([HCP MOA](https://www.amvuttrahcp.com/how-amvuttra-works), [PI](https://www.alnylamassist.com/sites/default/files/pdfdownloads/amvuttra-vutrisiran-product-characteristics.pdf)). It is indicated in adults for hATTR-PN and for ATTR-CM (wild-type or hereditary) to reduce CV death and events, and is administered as a low-volume SC injection every 3 months. Development and commercialization are led by Alnylam Pharmaceuticals; vutrisiran has orphan-drug designation in the US/EU and Fast Track designation in the US for hATTR-PN ([FDA risk review](https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215515Orig1s000RiskR.pdf), [Alnylam press](https://investors.alnylam.com/press-release?id=26776), [Fast Track PR](https://investors.alnylam.com/press-release?id=24771)).","Hereditary transthyretin amyloidosis (hATTR, ATTRv) is an autosomal dominant systemic amyloidosis caused by pathogenic variants in the TTR gene on chromosome 18, leading to misfolded TTR monomers that aggregate into amyloid fibrils and deposit in peripheral nerves, myocardium, GI tract, kidneys, and ocular tissues ([Poli 2023](https://www.frontiersin.org/articles/10.3389/fneur.2023.1242815/full)). Global prevalence of transthyretin familial amyloid polyneuropathy (ATTR-FAP) is estimated at ~5,000–10,000 diagnosed cases but true prevalence is likely higher due to under-diagnosis, with endemic foci in Portugal, Japan, and Sweden and growing recognition in non-endemic regions ([Schmidt 2018](https://pubmed.ncbi.nlm.nih.gov/29211930/)). THAOS registry data (>6,000 patients) highlight marked genotypic and phenotypic heterogeneity, with about one-quarter of symptomatic patients exhibiting mixed cardiac-neurologic involvement ([Gentile 2023](https://pubmed.ncbi.nlm.nih.gov/37946256/)). ATTR-CM (wtATTR and hATTR) primarily affects older adults (often men >60 years) and is frequently misdiagnosed; untreated ATTR-CM typically carries a median survival of ~2–5 years from diagnosis and substantial HF-related morbidity ([Tschöpe 2025](https://www.mdpi.com/2077-0383/14/13/4785), [ATTR-CM overview](https://www.verywellhealth.com/attr-cm-treatment-11758281)). Burden-of-illness studies show large impairments in physical functioning and HRQoL in hATTR-PN, comparable to or worse than diabetic neuropathy and CHF ([Yarlas 2019](https://pubmed.ncbi.nlm.nih.gov/31093980/)).","Alnylam developed vutrisiran (ALN-TTRSC02) as a next-generation, SC GalNAc-conjugated RNAi follow-on to patisiran, aiming for infrequent dosing with durable TTR knockdown and broad coverage of both hATTR and wtATTR phenotypes ([Alnylam FT designation PR](https://investors.alnylam.com/press-release?id=24771), [vutrisiran overview](https://newdrugapprovals.org/2022/06/17/vutrisiran-sodium-aln-65492-votrisiran/)). Vutrisiran received US orphan-drug designation (2018) and FDA Fast Track designation (2020) for hATTR-PN, with NDA acceptance in 2021 ([FDA risk review](https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215515Orig1s000RiskR.pdf), [NDA acceptance](https://investors.alnylam.com/press-release?id=24771)). The phase 3 HELIOS-A and HELIOS-B programs were designed to demonstrate efficacy across the full spectrum of ATTR amyloidosis (polyneuropathy and cardiomyopathy). Initial FDA approval for hATTR-PN was granted in June 2022 ([Alnylam 2022 PR](https://investors.alnylam.com/press-release?id=26776)), with sNDA expansion in March 2025 for ATTR-CM, making AMVUTTRA the first therapy approved in the US for both hATTR-PN and ATTR-CM ([Alnylam 2025 PR](https://investors.alnylam.com/press-release?id=28831), [ARCI news](https://arci.org/amvuttra-attr-cm-approval/)). EC approval for ATTR-CM followed in 2025 ([EC PR](https://www.businesswire.com/news/home/20250609199979/en/Alnylam-Receives-European-Commission-Approval-for-AMVUTTRA-vutrisiran-for-the-Treatment-of-ATTR-Amyloidosis-with-Cardiomyopathy)).","HELIOS-A (NCT03759379) was a global, phase 3, randomized, open-label study in adults with hATTR-PN comparing SC vutrisiran 25 mg Q3M vs IV patisiran 0.3 mg/kg Q3W, with efficacy primarily assessed vs an external placebo group from the APOLLO trial ([Adams 2023](https://pubmed.ncbi.nlm.nih.gov/35875890/), [CT.gov](https://clinicaltrials.gov/study/NCT03759379)). Patients had stage 1–2 polyneuropathy, diverse genotypes (V30M most common), and both endemic and non-endemic origins. At 18 months, vutrisiran produced substantial improvements vs external placebo in mNIS+7 (mean difference ≈ −30 points), Norfolk QoL-DN, gait speed, and other neurologic endpoints, while maintaining non-inferior TTR knockdown vs patisiran, with favorable safety (mainly mild injection-site reactions and vitamin A decrease) ([Adams 2023](https://pubmed.ncbi.nlm.nih.gov/35875890/), [HELIOS-A presentation](https://www.neurology.org/doi/10.1212/WNL.98.18_supplement.2974)). HELIOS-B (NCT04153149) was a double-blind, randomized trial in ATTR-CM (wtATTR and hATTR, with and without background tafamidis) comparing vutrisiran 25 mg Q3M vs placebo; over ≈36 months, vutrisiran significantly reduced the composite of all-cause mortality and recurrent CV events, improved or preserved 6MWD and KCCQ-OS, and reduced HF hospitalizations and urgent HF visits vs placebo ([Fontana 2024, NEJM](https://pubmed.ncbi.nlm.nih.gov/39213194/); [Witteles 2025, JACC](https://www.jacc.org/doi/10.1016/j.jacc.2025.04.008); [Alnylam 2024 ESC release](https://investors.alnylam.com/press-release?id=28411)). Pooled safety analyses across HELIOS-A/B show a consistent safety profile with no major hepatic or hematologic signal and low rates of treatment discontinuation ([Witteles 2025 safety pooled](https://www.jacc.org/doi/10.1016/j.jacadv.2025.102066)).","Formal cost-effectiveness models for vutrisiran are emerging but remain limited. A Canadian CADTH pharmacoeconomic review of vutrisiran for hATTR-PN concluded that, at sponsor-submitted pricing, vutrisiran was not cost-effective vs patisiran, with an ICER ≈ CA$2.8M per QALY gained and 0% probability of being cost-effective at CA$50,000/QALY; incremental benefit was almost entirely driven by administration-related utilities, not large differences in survival or disease progression ([NCBI CADTH table](https://www.ncbi.nlm.nih.gov/books/NBK602494/table/t05/), [CADTH report](https://www.ncbi.nlm.nih.gov/books/NBK602494/), [pharmacoecon details](https://www.ncbi.nlm.nih.gov/books/n/tr8269868382080182/tr8269868382080182_ch02_bp1/)). The same report estimated a 3-year incremental budget impact ≈CA$23.8M for Canadian public plans if reimbursing vutrisiran for hATTR-PN ([NCBI budget impact](https://www.ncbi.nlm.nih.gov/books/NBK602494/)). A UK-based modeling/administration cost comparison of RNAi therapies suggested that, over 10 years, per-patient administration costs are dramatically lower for quarterly SC vutrisiran vs q3-week IV patisiran (£127 vs £7,699), supporting a potential economic advantage from reduced infusion-center resource use ([Kumar 2023, Value Health](https://www.valueinhealthjournal.com/article/S1098-3015(23)03901-3/fulltext)). ICER’s 2024 evidence report for ATTR-CM evaluated tafamidis and acoramidis and concluded these agents would meet typical US cost-effectiveness thresholds if priced ~$13,600–$39,000/year, but did not model vutrisiran due to then-immature data, instead qualitatively noting its favorable dosing and TTR-silencing mechanism ([ICER 2024 draft/final report](https://icer.org/wp-content/uploads/2024/10/ATTR-CM_RAAG_October-2024.pdf), [ICER press](https://icer.org/news-insights/press-releases/icer-publishes-final-evidence-report-attr-cm/)). Tafamidis cost-effectiveness analyses in the US highlight system-level pressure: initial ICERs ≈$880,000/QALY at list price ~$225k/year, requiring ~90% price reductions to reach conventional thresholds ([Kazi 2020, Circulation](https://pubmed.ncbi.nlm.nih.gov/32078382/), [JWatch summary](https://www.jwatch.org/na51050/2020/03/11/paying-price-transthyretin-amyloid-cardiomyopathy)). Recent commentary on rare CV therapies notes ATTR-CM agents (tafamidis, acoramidis, vutrisiran) now priced ≈$244k–$500k/year, with risk of access disparities and aggressive utilization management ([Decker 2024](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2823651), [CardiovascularBusiness 2025](https://cardiovascularbusiness.com/topics/clinical/pharmaceutics/high-cost-cardiac-amyloidosis-drugs-may-limit-access-low-income-patients)). NICE and other HTA bodies are actively assessing vutrisiran for ATTR-CM; early communications indicate conditional recommendations with confidential discounts based on CV event reduction and QoL benefit balanced against high list price ([Reuters 2025 on NICE recommendation](https://www.reuters.com/business/healthcare-pharmaceuticals/uks-drug-cost-watchdog-recommends-alnylams-heart-disease-drug-2025-11-21/)).","Real-world evidence specific to vutrisiran is just emerging. A retrospective claims-database analysis of vutrisiran-treated ATTR-CM patients (AHA 2025 abstract) reported substantial ongoing healthcare resource utilization and costs (≈37% hospitalized annually; substantial HF-related costs) despite therapy, underscoring residual unmet need and the importance of earlier diagnosis and broader disease management ([vutrisiran HCRU abstract](https://www.ahajournals.org/doi/abs/10.1161/circ.152.suppl_3.4369360), [ResearchGate summary](https://www.researchgate.net/publication/397257799_Abstract_4369360_Vutrisiran_Healthcare_Resource_Utilization_Costs_Discontinuation_and_Mortality_a_Retrospective_Database_Analysis)). Global observational registries such as THAOS provide rich longitudinal data on survival, phenotype, and treatment patterns across tafamidis, patisiran, inotersen, and (in more recent years) vutrisiran; analyses demonstrate substantial mortality benefit with tafamidis in ATTR-CM and highlight the mixed cardiac-neurologic phenotype in many patients ([Gentile 2023 THAOS](https://pubmed.ncbi.nlm.nih.gov/37946256/), [Garcia-Pavia 2025 THAOS tafamidis](https://pubmed.ncbi.nlm.nih.gov/38909877/)). Real-world treatment-management series show growing switches from tafamidis and patisiran to vutrisiran driven primarily by preference for SC dosing and extended 3-monthly interval, as well as tolerability considerations ([Dieu 2025 real-world management](https://neurolrespract.biomedcentral.com/articles/10.1186/s42466-025-00428-6)). Broader ATTR-CM RWE (largely tafamidis-based) indicates that real-world patients are older, more comorbid, and more likely to have mixed phenotypes than trial populations, with somewhat attenuated but still meaningful survival benefits vs natural history ([Wixner 2024/2025 ATTR-CM survival](https://pubmed.ncbi.nlm.nih.gov/40632476/), [THAOS analyses](https://www.researchgate.net/publication/375549281_A_15-year_consolidated_overview_of_data_in_over_6000_patients_from_the_Transthyretin_Amyloidosis_Outcomes_Survey_THAOS)).","Validated PROs used in trials relevant to vutrisiran include Norfolk QoL-DN (neuropathy-related QoL), mNIS+7 (composite neurologic impairment), modified Rankin Scale, 6MWD, KCCQ-OS, NYHA class, and generic measures (EQ-5D, SF-36/SF-12). In HELIOS-A, vutrisiran led to clinically meaningful improvements vs external placebo in Norfolk QoL-DN and smaller neurologic impairment (mNIS+7), with a substantial proportion of patients experiencing stabilization or improvement in neuropathy and functional status over 18 months, consistent with disease modification rather than mere slowing of decline ([Adams 2023](https://pubmed.ncbi.nlm.nih.gov/35875890/)). APOLLO and other RNAi trials in hATTR-PN demonstrate that large TTR reductions translate into improved or preserved PROs, particularly in physical functioning domains, supporting TTR knockdown as a patient-centered mechanism ([Obici 2020](https://www.tandfonline.com/doi/full/10.1080/13506129.2020.1730790), [Yarlas 2019](https://pubmed.ncbi.nlm.nih.gov/31093980/)). In HELIOS-B, vutrisiran improved or preserved 6MWD and KCCQ-OS vs placebo, indicating sustained benefit on functional capacity and HF-related QoL in ATTR-CM ([Fontana 2024 NEJM](https://pubmed.ncbi.nlm.nih.gov/39213194/)). ATTR-specific QoL instruments (e.g., ATTR-QoL) are being validated, which may allow more nuanced capture of multisystem burden and treatment benefit in future RWE and HEOR studies ([Lovley 2025 ATTR-QoL](https://jpro.springeropen.com/articles/10.1186/s41687-025-00880-7)).","Competitive therapies in ATTR include tafamidis (Vyndaqel/Vyndamax, oral TTR stabilizer, once daily), acoramidis (ATTRUBY, oral stabilizer), patisiran (Onpattro, IV RNAi q3w), inotersen (Tegsedi, weekly SC antisense oligonucleotide), diflunisal (off-label TTR stabilizing NSAID), and emergent agents in development. Tafamidis and acoramidis primarily stabilize TTR without reducing production; patisiran and vutrisiran silence TTR production; inotersen reduces TTR via antisense mechanisms ([Tschöpe 2025 review](https://www.mdpi.com/2077-0383/14/13/4785), [ICER ATTR-CM report](https://icer.org/wp-content/uploads/2024/10/ATTR-CM_RAAG_October-2024.pdf), [Verywell ATTR-CM treatments overview](https://www.verywellhealth.com/attr-cm-treatment-11758281), [acoramidis approval](https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-bridgebios-drug-rare-heart-condition-2024-11-23/)). Vutrisiran’s key clinical differentiators include potent, durable TTR knockdown with Q3M SC dosing (no infusion center), efficacy across both hATTR-PN and ATTR-CM (including patients already on tafamidis in HELIOS-B), and a generally favorable safety profile with manageable vitamin A supplementation. HELIOS-B suggests that vutrisiran provides incremental CV benefit in an ATTR-CM population more reflective of current clinical practice, including multi-morbid and tafamidis-treated patients, supporting potential positioning as a backbone disease-modifying therapy in both mono- and combination strategies ([Fontana 2024](https://pubmed.ncbi.nlm.nih.gov/39213194/), [Alnylam ESC release](https://investors.alnylam.com/press-release?id=28411), [FT trial commentary](https://www.ft.com/content/cb16cf65-4b80-4027-9478-474d3b47e1e1)).","US list price for AMVUTTRA in ATTR-CM has been reported at ~$119,351 per prefilled syringe administered Q3M, implying an annual WAC approaching ~$477k, placing it among the highest-priced CV therapies and in the range of or above tafamidis and acoramidis ([Reuters 2025 pricing](https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-alnylams-drug-rare-heart-condition-2025-03-20/), [CardiovascularBusiness 2025](https://cardiovascularbusiness.com/topics/clinical/pharmaceutics/high-cost-cardiac-amyloidosis-drugs-may-limit-access-low-income-patients)). FDA approvals (2022 hATTR-PN; 2025 ATTR-CM) and orphan/fast-track designations support coverage, but payers typically impose strict prior authorization: confirmed hATTR pathogenic variant or documented ATTR-CM (scintigraphy/biopsy), appropriate NYHA class (often I–III), exclusion of advanced HF, and sometimes failure/intolerance of other disease-modifying therapies, with re-authorization tied to stability or improvement in functional status and absence of major safety issues ([PI](https://www.alnylamassist.com/sites/default/files/pdfdownloads/amvuttra-vutrisiran-product-characteristics.pdf), [BCBS coverage guideline example](https://mcgs.bcbsfl.com/MCG?mcgId=09-J4000-32&pv=false)). ICER and other HTA bodies have highlighted affordability concerns for ATTR-CM therapies overall, prompting expectation of significant confidential rebates/discounts and close management, including specialty-pharmacy distribution, site-of-care steering, and potential step-through or combination-therapy policies ([ICER ATTR-CM report](https://icer.org/news-insights/press-releases/icer-publishes-final-evidence-report-attr-cm/), [Nikitin 2025 JMCP](https://www.jmcp.org/doi/10.18553/jmcp.2025.31.3.323)). NICE has signaled support for NHS use of vutrisiran in ATTR-CM pending final guidance, suggesting that, at negotiated UK prices, cost-effectiveness thresholds can be met for a defined high-risk population ([Reuters UK NICE piece](https://www.reuters.com/business/healthcare-pharmaceuticals/uks-drug-cost-watchdog-recommends-alnylams-heart-disease-drug-2025-11-21/)).","Current evidence gaps for vutrisiran include: (1) limited long-term (>5–10 year) survival and CV outcome data beyond HELIOS-B’s 3–3.5-year horizon; (2) absence of mature, peer-reviewed cost-effectiveness models in US payers specifically for vutrisiran in ATTR-CM; (3) sparse RWE comparing vutrisiran head-to-head vs tafamidis, acoramidis, patisiran, and inotersen across mixed cardiac-neurologic phenotypes; and (4) limited PRO and caregiver-burden data in real-world practice. For PANTHERx, opportunities include: designing a specialty-pharmacy-anchored registry of ATTR patients receiving vutrisiran (and comparators) with standardized capture of phenotype, genotype, disease stage, comorbidities, dosing and adherence, switches, and persistence; embedding routine PROs (Norfolk QoL-DN, KCCQ-OS, 6MWD or patient-reported walking tolerance/ADLs, ATTR-QoL where feasible) into clinical workflows; conducting payer-relevant cost-effectiveness or budget-impact analyses using actual PANTHERx medication costs, distribution/administration patterns, and admitted vs outpatient utilization; analyzing treatment sequencing (e.g., tafamidis → vutrisiran, or combination therapy) and outcomes; and performing trial-to-RWE gap analyses comparing HELIOS-A/B inclusion criteria and outcomes vs the more heterogeneous patient population (older age, CKD, AF, multi-system involvement). These projects would generate high-value HEOR/RWE insights for both internal decision-making and external publications, positioning pharmacies as a key real-world data partner in ATTR amyloidosis.",
drug2,ARIKAYCE®,amikacin liposome inhalation,Insmed Incorporated,https://www.pantherxrare.com/wp-content/uploads/2019/07/arikayce-smaller.png,Refractory MAC lung disease (NTM),https://dailymed.nlm.nih.gov/dailymed/medguide.cfm?setid=499ab990-2b21-474f-aaba-d86388965f40,"590 mg (one vial) once daily via oral inhalation using the Lamira nebulizer system, administered at home as add-on to a macrolide-based multidrug background regimen",Proportion of patients achieving sputum culture conversion (three consecutive negative cultures) by Month 6 in the CONVERT trial; durability of conversion and safety endpoints in ARISE and ENCORE,"Real-world culture conversion and relapse rates, pulmonary exacerbation and hospitalization rates, treatment persistence and discontinuation, respiratory AE–related healthcare utilization","Changes in respiratory symptom and HRQoL scores using tools such as QOL-B Respiratory Domain and SGRQ, plus patient global impression of change","ARIKAYCE is a liposomal formulation of amikacin for inhalation that delivers high local aminoglycoside concentrations to the airways while limiting systemic exposure. Amikacin inhibits bacterial protein synthesis via binding the 30S ribosomal subunit, and liposomal encapsulation facilitates penetration into biofilm and intracellular niches of MAC. It is dosed as 590 mg once daily via the Lamira nebulizer system as add-on therapy in adults with refractory MAC lung disease. The product was developed by Insmed and approved by FDA in 2018 under the Limited Population Pathway (LPAD) for patients with limited or no alternative treatment options.","Refractory MAC pulmonary disease is a chronic NTM infection typically affecting older adults with bronchiectasis or structural lung disease, characterized by cough, sputum, fatigue, weight loss and progressive radiographic damage. MAC is the most common NTM species complex in North America and Europe, and a subset of patients fail to convert cultures despite prolonged guideline-based multidrug therapy. These patients experience high symptom burden, recurrent exacerbations and increased mortality compared with non-NTM bronchiectasis. HRQoL is markedly impaired across physical and psychosocial domains, and there is a clear unmet need for effective, well-tolerated options to achieve culture conversion and prevent progressive lung damage.","ARIKAYCE was developed to address the need for targeted delivery of amikacin directly to MAC-infected lung regions while minimizing systemic toxicity seen with IV aminoglycosides. Early phase studies demonstrated safety, lung deposition and microbiologic activity, supporting advancement to the pivotal CONVERT Phase 3 trial in refractory MAC lung disease. CONVERT compared ARIKAYCE plus guideline-based therapy to guideline therapy alone and used culture conversion as the primary endpoint; positive results led to FDA approval under LPAD for a limited refractory population. Extension and follow-up studies (e.g., ARISE and ENCORE) were initiated as post-approval commitments to further characterize long-term safety, effectiveness and patient-reported outcomes.","In CONVERT, adults with refractory MAC lung disease on guideline-based therapy were randomized 2:1 to ARIKAYCE plus background regimen versus background regimen alone. Culture conversion by Month 6 was significantly higher with ARIKAYCE (about one third of patients) versus control, with many responders maintaining conversion over follow-up. Safety was acceptable but characterized by respiratory events such as dysphonia, cough and bronchospasm, and a small risk of hypersensitivity pneumonitis, necessitating careful monitoring. Subsequent analyses and additional trials have reinforced the microbiologic benefit and clarified the benefit–risk profile, though hard outcomes such as survival and long-term lung function remain less well quantified.","Published pharmacoeconomic evaluations suggest ARIKAYCE is a high-cost therapy with uncertain cost-effectiveness at current prices because evidence linking culture conversion to long-term survival and hospitalization reductions is limited. National HTA bodies have highlighted high drug acquisition costs and considerable uncertainty around quality-adjusted life-year gains, often placing the ICER above conventional thresholds. Potential value drivers include the avoidance of ongoing multidrug regimens, prevention of progressive structural damage and reduced need for hospitalizations or surgery, but these are not yet fully captured in models. Payers therefore tend to restrict use to truly refractory cases where incremental microbiologic benefit is most compelling and rely on specialty pharmacy programs to support adherence and manage adverse events.","Real-world evidence from observational cohorts and registries shows that ARIKAYCE is being used primarily in older, comorbid patients with refractory MAC lung disease, with culture-conversion rates and safety patterns broadly consistent with trial findings but somewhat more heterogeneous. RWE highlights challenges with inhalation technique, treatment adherence and respiratory tolerability, emphasizing the role of education and close follow-up. These data also underscore the variability in treatment duration and decisions around continuation vs discontinuation after culture conversion. More robust RWE linking ARIKAYCE use to long-term outcomes such as lung function trajectories, hospitalization trends and survival is still needed.","Patient-reported outcome work demonstrates that successful culture conversion and symptom control with ARIKAYCE can translate into meaningful improvements in respiratory symptoms, fatigue and daily functioning. Instruments such as QOL-B and SGRQ show better scores in responders compared with non-responders, supporting the clinical relevance of microbiologic outcomes. Patients also report improved confidence in physical activity and social participation when cough and sputum are reduced. However, treatment burden from daily nebulization and respiratory adverse events can offset some perceived benefit, making shared decision-making important.","Compared with systemic aminoglycosides, ARIKAYCE offers targeted inhaled delivery with reduced systemic nephrotoxicity and ototoxicity, but with an increased risk of local respiratory adverse events. Within the NTM landscape, it is positioned as the only FDA-approved therapy specifically indicated for refractory MAC lung disease as add-on to guideline-based regimens. It competes with off-label regimen modifications, alternative injectable agents and supportive strategies, and is typically reserved for culture-positive, treatment-refractory patients. Its unique mechanism and LPAD indication support a niche but important role in an otherwise underserved population.","US payers generally require documentation of refractory MAC (persistent positive cultures after ≥6 months of guideline therapy), use as part of a combination regimen and specialist prescribing for ARIKAYCE. Prior authorization often includes microbiologic and radiographic evidence and may require demonstration of adherence to background therapies. Coverage is through specialty pharmacy benefits with high list prices and reliance on copay assistance programs. Budget impact concerns and uncertain long-term cost-effectiveness encourage tight utilization management and periodic reassessment of benefit.","Research gaps include long-horizon models that connect culture conversion with survival, hospitalizations and HRQoL, and more definitive RWE on long-term outcomes in routine practice. There is a need to identify predictors of response and relapse, optimize treatment duration and characterize outcomes after discontinuation. Additional PRO research could quantify the trade-off between symptom relief and treatment burden. Specialty pharmacies can contribute by capturing adherence, inhalation technique, clinical outcomes and utilization data to inform HEOR studies and value-based access agreements.","Research gaps include long-horizon models that connect culture conversion with survival, hospitalizations and HRQoL, and more definitive RWE on long-term outcomes in routine practice. There is a need to identify predictors of response and relapse, optimize treatment duration and characterize outcomes after discontinuation. Additional PRO research could quantify the trade-off between symptom relief and treatment burden. Specialty pharmacies can contribute by capturing adherence, inhalation technique, clinical outcomes and utilization data to inform HEOR studies and value-based access agreements."
drug3,ATTRUBY™,acoramidis,"BridgeBio Pharma / Eidos Therapeutics, Inc.",https://www.pantherxrare.com/wp-content/uploads/2025/02/AustedoLogo.jpg,ATTR-CM (cardiomyopathy),https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=913552ef-875d-4cb7-bf05-a7d20a394c38,"712 mg orally twice daily (equivalent to 800 mg acoramidis hydrochloride), with or without food, tablets swallowed whole","Primary hierarchical composite endpoint in ATTRibute-CM including all-cause mortality, cardiovascular hospitalization, change in NT-proBNP and change in 6-minute walk distance over 30 months; key secondary endpoints include KCCQ overall summary score and NYHA class","All-cause and cardiovascular mortality, cardiovascular hospitalization rates, NT-proBNP trajectories, cardiac imaging parameters, functional status, treatment persistence and switching patterns","Changes in KCCQ overall summary and domain scores, EQ-5D utilities, NYHA class, patient global assessment and other HF-related PROs","Acoramidis is an oral, high-affinity transthyretin (TTR) stabilizer that binds to the thyroxine-binding sites of wild-type and mutant TTR tetramers, preventing dissociation into monomers that misfold and form amyloid fibrils. It achieves near-complete TTR stabilization at steady state, aiming to halt or slow ATTR-CM progression by stabilizing the circulating protein rather than reducing its production. It is administered as 712 mg twice daily (800 mg acoramidis hydrochloride) with or without food. BridgeBio, via Eidos Therapeutics, developed acoramidis, which received FDA approval in 2024 for treatment of cardiomyopathy of wild-type or variant ATTR to reduce cardiovascular death and HF hospitalizations.","ATTR-CM is an infiltrative cardiomyopathy caused by myocardial deposition of misfolded TTR amyloid, leading to restrictive physiology, HFpEF, arrhythmias and conduction disorders. It can arise from wild-type TTR (age-related) or pathogenic TTR variants and is increasingly recognized in older adults, particularly men, via bone scintigraphy and advanced imaging. Untreated ATTR-CM carries high morbidity with dyspnea, fatigue, edema and recurrent HF admissions and has median survival of around 2–5 years after diagnosis in historical cohorts. Global prevalence is under-estimated but likely in the hundreds of thousands as awareness grows. Unmet needs include earlier diagnosis, interventions that improve hard outcomes and therapy options for patients who progress on or are ineligible for other stabilizers.","Acoramidis was developed on the hypothesis that more complete and sustained TTR stabilization could deliver greater clinical benefit compared with earlier stabilizers like tafamidis. Early-phase studies demonstrated favorable pharmacokinetics, robust TTR stabilization and tolerability, supporting progression to Phase 2 and open-label extension cohorts. The pivotal Phase 3 ATTRibute-CM trial randomized patients with wild-type or variant ATTR-CM to acoramidis or placebo for 30 months and used a hierarchical composite endpoint of mortality, cardiovascular hospitalization, NT-proBNP and 6-minute walk distance. Positive outcomes led to regulatory submissions and FDA approval, with post-approval work including additional regional trials and long-term extension analyses to characterize durability, safety and outcomes in broader populations.","In ATTRibute-CM, acoramidis improved the hierarchical composite endpoint versus placebo, driven by reductions in cardiovascular hospitalizations, favorable NT-proBNP and 6-minute walk trajectories and signals of improved survival. Patients on acoramidis showed stabilization or modest improvement in functional and biomarker measures compared with deterioration on placebo, indicating disease-modifying effects in ATTR-CM. Safety was generally similar to placebo, with mainly mild gastrointestinal and general adverse events and low discontinuation rates. Longer-term extension data suggest sustained TTR stabilization and persistent benefit over several years, although head-to-head data versus other disease-modifying therapies are lacking.","Early economic assessments extrapolating from ATTRibute-CM suggest acoramidis will be a high-cost, disease-modifying therapy with potential to reduce cardiovascular hospitalizations and preserve quality of life but with uncertain cost-effectiveness at orphan-level prices. Experience with tafamidis shows that ATTR-CM therapies can generate ICERs well above traditional thresholds unless substantial discounts or value-based arrangements are in place. For acoramidis, key value drivers are the magnitude and durability of hospitalization and survival benefits and its oral dosing convenience relative to RNAi-based silencers. Payers will weigh these benefits against budget impact and may limit use to earlier-stage patients or those at high risk where absolute benefit is greatest.","Real-world evidence for acoramidis is emerging as post-approval cohorts, registries and claims studies accumulate data on utilization, adherence and outcomes. Early RWE will focus on confirming trial-like reductions in cardiovascular hospitalization and stability in functional measures in older, more comorbid patients. Registries such as THAOS and ATTR-focused cardiomyopathy cohorts are expected to capture acoramidis use alongside other stabilizers and silencers, enabling comparative effectiveness analyses. These data will be important for validating model assumptions used in economic evaluations and guiding payer and guideline decisions on optimal sequencing.","PRO data from ATTRibute-CM demonstrate that acoramidis can stabilize or improve KCCQ scores compared with placebo, consistent with better HF-related HRQoL and daily functioning. Changes in 6-minute walk distance and NYHA class support improved exercise tolerance and symptom burden, outcomes that matter directly to patients. Generic measures such as EQ-5D show preservation of utility scores relative to declining trajectories in placebo groups. Future PRO work in routine practice can provide more granular insight into domains such as fatigue, orthostatic symptoms and emotional burden and how these respond to long-term treatment.","Within the ATTR-CM treatment landscape, acoramidis joins tafamidis as a TTR stabilizer and competes with RNAi silencers (e.g., vutrisiran) that reduce TTR production. Its differentiators include near-complete TTR stabilization, twice-daily oral dosing and robust composite cardiovascular outcomes in a modern trial. Compared with tafamidis, acoramidis may offer incremental benefit in some subgroups, but no head-to-head data exist; compared with silencers, it offers oral convenience but does not address extrahepatic TTR production. Clinicians will individualize choice based on disease stage, comorbidities, prior therapy, and patient preferences around injections versus oral regimens.","Payers are likely to manage acoramidis similarly to other high-cost ATTR-CM therapies, requiring confirmed diagnosis by appropriate imaging or biopsy, documentation of wild-type or variant ATTR and restriction to NYHA class I–III. Prior authorization may require baseline NT-proBNP, imaging and functional assessments and periodic reassessment to justify continued coverage. High drug costs and increasing ATTR-CM prevalence may prompt step therapy policies (e.g., tafamidis first) or preference for certain agents within plan formularies. Access will also depend on manufacturer discounts, outcomes-based contracts and availability of patient assistance programs to mitigate out-of-pocket burden.","Key research needs include robust cost-effectiveness and budget impact studies using mature trial and RWE data, comparative effectiveness and economic modeling versus tafamidis and RNAi therapies, and long-term safety and effectiveness in diverse real-world populations. Registries should evaluate acoramidis treatment patterns, sequencing and combination strategies with other ATTR therapies. Specialty pharmacy–anchored RWE can characterize adherence, persistence, PROs and healthcare utilization and inform payer negotiations and value-based contracts. Further research is also needed on optimal timing of initiation (e.g., early disease vs advanced) to maximize absolute benefit.","Key research needs include robust cost-effectiveness and budget impact studies using mature trial and RWE data, comparative effectiveness and economic modeling versus tafamidis and RNAi therapies, and long-term safety and effectiveness in diverse real-world populations. Registries should evaluate acoramidis treatment patterns, sequencing and combination strategies with other ATTR therapies. Specialty pharmacy–anchored RWE can characterize adherence, persistence, PROs and healthcare utilization and inform payer negotiations and value-based contracts. Further research is also needed on optimal timing of initiation (e.g., early disease vs advanced) to maximize absolute benefit."
drug4,AUSTEDO™ / XR,deutetrabenazine,Teva Pharmaceutical Industries Ltd.,https://www.pantherxrare.com/wp-content/uploads/2025/02/AustedoLogo.jpg,Huntington chorea; tardive dyskinesia,https://dailymed.nlm.nih.gov/dailymed/medguide.cfm?setid=7ea3c60a-45c7-44cc-afc2-d87fa53993c0,"IR AUSTEDO is typically initiated at 6 mg once daily and titrated by 6 mg/day weekly to an individualized total daily dose divided twice daily (maximum 48 mg/day); AUSTEDO XR is titrated as a once-daily extended-release formulation, with lower maximum doses when coadministered with strong CYP2D6 inhibitors","Change from baseline in AIMS total score at Week 12 in TD trials; change from baseline in UHDRS Total Maximal Chorea score in HD trials; responder analyses (e.g., ≥50% AIMS reduction) and CGI-based global improvement assessments","Real-world measures include persistence and adherence to deutetrabenazine, dose titration patterns, changes in AIMS or UHDRS scores in routine practice, psychiatric adverse event rates, healthcare utilization and treatment patterns versus other VMAT2 inhibitors","Patient- and clinician-reported outcomes capturing movement severity (AIMS, UHDRS), CGI scales, disease-specific QoL instruments in TD registries and generic HRQoL tools assessing social functioning, daily activities and mental health","Deutetrabenazine is a reversible vesicular monoamine transporter 2 (VMAT2) inhibitor that reduces vesicular storage and synaptic release of dopamine and other monoamines, thereby attenuating hyperkinetic involuntary movements in Huntington’s chorea and tardive dyskinesia. Deuterium incorporation slows metabolism and allows more stable exposure versus tetrabenazine, enabling less frequent dosing and improved tolerability. AUSTEDO IR is dosed twice daily after titration, while AUSTEDO XR allows once-daily dosing with comparable exposure. Teva developed deutetrabenazine, with AUSTEDO first approved in 2017 for HD chorea and later for TD, and AUSTEDO XR approved subsequently as a once-daily formulation.","Huntington’s disease is an autosomal dominant neurodegenerative disorder caused by CAG expansion in the HTT gene and characterized by chorea, cognitive decline and psychiatric symptoms; chorea impairs gait, swallowing and daily functioning and contributes to injury risk and caregiver burden. Tardive dyskinesia is an iatrogenic movement disorder from chronic dopamine receptor blockade (e.g., antipsychotics) with repetitive, involuntary movements that can be socially stigmatizing and functionally disabling. TD prevalence is substantial among long-term antipsychotic users, especially older adults and those with high cumulative exposure. Both conditions are associated with impaired HRQoL, reduced adherence to primary psychiatric regimens and increased healthcare utilization, creating a high unmet need for targeted, well-tolerated movement-disorder therapies.","Development of deutetrabenazine built on VMAT2 inhibition experience with tetrabenazine but aimed to improve pharmacokinetics and tolerability via deuterium substitution. Early-phase studies characterized safety, VMAT2 target engagement and dose–response, followed by randomized trials in HD chorea and TD comparing deutetrabenazine to placebo using standardized movement scales. Positive Phase 2/3 results led to FDA approval for HD chorea and TD, with AUSTEDO XR added later to provide once-daily dosing. Post-approval commitments include long-term safety and effectiveness studies and real-world registries such as IMPACT-TD to better characterize outcomes in broader clinical populations.","Randomized controlled trials in TD have shown deutetrabenazine significantly reduces AIMS scores at 12 weeks compared with placebo and yields higher responder proportions, with benefits maintained in long-term extension studies. In HD chorea, deutetrabenazine improves UHDRS chorea scores and global impressions of change, with individualized titration allowing balancing of efficacy and tolerability. Safety concerns include depression and suicidality in HD, parkinsonism, somnolence and QT prolongation, reflected in labeling warnings and monitoring recommendations, but overall tolerability appears better than tetrabenazine. Real-world and extension data support sustained benefit with careful patient selection and monitoring.","ICER’s assessment of VMAT2 inhibitors found deutetrabenazine and valbenazine provide meaningful improvements in TD symptoms but at high cost, yielding ICERs well above conventional thresholds. Deutetrabenazine’s economic value is driven largely by HRQoL gains and functional improvements rather than reductions in major medical events, as TD and HD chorea are chronic symptomatic conditions. Once-daily XR dosing may indirectly improve adherence and drive additional value, but formal comparative economic analyses between IR and XR formulations are limited. Payers typically manage budget impact through prior authorization, VMAT2 step therapy and negotiated discounts, while manufacturer assistance mitigates patient out-of-pocket burden.","Real-world studies and registries such as IMPACT-TD indicate that deutetrabenazine treatment leads to durable reductions in TD movements and improvements in functioning, with safety profiles broadly consistent with trials. Observational analyses document typical titration patterns, persistence rates and reasons for discontinuation, providing actionable insights for clinicians in everyday practice. Post-marketing safety databases show the importance of monitoring psychiatric and movement-related adverse events but do not reveal new major safety signals to date. These data extend trial evidence into more heterogeneous patient populations and support long-term use in appropriately selected patients.","PRO data show that improvements in AIMS and UHDRS scores with deutetrabenazine translate into better patient- and clinician-rated global impressions and QoL, including less embarrassment, better speech and eating and improved social engagement. TD registries demonstrate that untreated TD severely impacts domains such as self-image, social functioning and adherence to psychiatric care, and that effective VMAT2 inhibition can reverse some of these burdens. Sustained PRO improvements over months to years help justify ongoing therapy despite high drug costs. Future research may further refine which patient subgroups derive the largest QoL gains per unit of movement reduction.","Deutetrabenazine competes with valbenazine for TD and with tetrabenazine and off-label regimens for HD chorea. Indirect comparisons suggest broadly similar efficacy between deutetrabenazine and valbenazine in TD, with nuanced differences in dosing schedules, half-life and side-effect profiles. Deutetrabenazine’s deuteration and availability in both IR and XR formulations offer flexibility and may improve adherence and tolerability relative to tetrabenazine. Specialty pharmacy positioning emphasizes its role as a high-impact symptomatic therapy for patients with moderate to severe TD or HD chorea whose functional or social impairment justifies VMAT2 inhibition.","Payers generally place AUSTEDO and AUSTEDO XR on specialty or high tiers with prior authorization criteria requiring confirmed TD or HD chorea, significant functional impairment and inadequate response to dose optimization or switching of antipsychotics when feasible. Policies may require baseline and follow-up AIMS or UHDRS documentation, psychiatric evaluation and limits on maximum dose, with periodic reauthorization based on continued benefit. Budget impact concerns encourage use of step therapy within the VMAT2 class and negotiation of rebates, while patient support programs are important for minimizing financial barriers.","Research opportunities include updated cost-effectiveness analyses using real-world price and effectiveness data, and studies that link symptom improvements to downstream outcomes such as employment, caregiver burden and psychiatric treatment adherence. Comparative RWE and economic modeling versus valbenazine and future agents would clarify optimal sequencing and identify patients most likely to benefit from deutetrabenazine. Specialty-pharmacy based registries can provide detailed data on adherence, titration, PROs and healthcare utilization to inform payers, guideline developers and clinical practice.","Research opportunities include updated cost-effectiveness analyses using real-world price and effectiveness data, and studies that link symptom improvements to downstream outcomes such as employment, caregiver burden and psychiatric treatment adherence. Comparative RWE and economic modeling versus valbenazine and future agents would clarify optimal sequencing and identify patients most likely to benefit from deutetrabenazine. Specialty-pharmacy based registries can provide detailed data on adherence, titration, PROs and healthcare utilization to inform payers, guideline developers and clinical practice."